However, these studies fail to show any benefit in prostate cancer-specific survival (PCSS) or PSA relapse-free survival [27, 28], and therefore neoadjuvant ADT before RP is not recommended by the EAU guidelines [24]. The gene discussed is KLK3; the disease is Familial prostate cancer.